CytoDyn CMO Scott A. Kelly resigns effective immediately

CytoDyn Inc.

Scott A. Kelly, M.D., resigns as Chief Medical Officer of CytoDyn on December 19, 2022.
Resignation effective immediately; no reason provided in the filing.
No replacement named; search for new CMO presumably underway.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Scott A. Kelly M.D.

Chief Medical Officer

CYDY · CytoDyn Inc.

Effective: 2022-12-19
Filed: December 19, 2022, 6:59 PM ET

On December 19, 2022, the Company and Scott A. Kelly M.D., the Company’s Chief Medical Officer, agreed that Dr. Kelly will resign from his role at the Company, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Scott A. Kelly M.D. resigned as Chief Medical Officer at CytoDyn Inc..

Action: resigned
Role: Chief Medical Officer

Exact text from the filing

On December 19, 2022, the Company and Scott A. Kelly M.D., the Company’s Chief Medical Officer, agreed that Dr. Kelly will resign from his role at the Company, effective immediately.

View on SEC.gov

CytoDyn Inc. filing history →

Source: SEC EDGAR

accession 0001558370-22-018797

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.